Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?  

While IL-5/IL5 receptor blockade has been shown to be efficacious in treating "eosinophilic" manifestations of EGPA, including asthma and nasal polyps, there are real-world studies that demonstrate its effectiveness in what we consider "vasculitic" manifestations of the disease as well. I personally...